Background. The need for an effective vaccine against human tuberculosis has driven the development of different candidates and vaccination strategies. Novel live attenuated vaccines are being developed that promise greater safety and efficacy than BCG against tuberculosis. We combined BCG with the vaccine MTBVAC to evaluate whether the efficacy of either vaccine would be affected upon revaccination.
Tuberculosis remains one of the deadliest diseases that are present in all regions of the world. In 2015, an estimated 10.4 million people developed tuberculosis, and 1.8 million died from the disease [1] . The incidence of tuberculosis is slowly declining each year, but, given that most deaths from tuberculosis are preventable, the death toll is still unacceptably high. The World Health Organization (WHO) has developed a post-2015 global tuberculosis strategy, the goal of which is to end the global tuberculosis epidemic, with corresponding 2035 targets of a 95% reduction in deaths and a 90% reduction in incidence (compared with 2015) [2] . The only licensed vaccine, BCG, is widely used and provides protection against tuberculosis-associated meningitis and disseminated tuberculosis in children. However, the efficacy of the vaccine in preventing pulmonary tuberculosis is unclear, with studies showing 0%-80% protection [3] . Mass vaccination of adults in countries with a high burden of tuberculosis with a new, effective tuberculosis vaccine will be key to the global elimination of tuberculosis [4, 5] , and development of such a vaccine is an international research priority [2] .
A common strategy for tuberculosis vaccine development is to enhance the protection due to neonatal BCG vaccination by delivering a second vaccine to boost immune responses to targeted antigens of Mycobacterium tuberculosis. This is regarded as heterologous boosting, since the boost vaccines are subunit approaches consisting of single or multiple antigen targets delivered as a protein in adjuvant (H1, H4, M72, ID93, and HBHA) [6, 7] or viral vectors (MVA85A, Ad85A, and Aeras402) [6] . Revaccination with BCG (homologous boosting) has been considered and evaluated both clinically and in animal models. Multiple BCG vaccinations in animal models show variable effects on protective efficacy, ranging from improved efficacy [8] to exacerbated disease [9] , but differences in experimental design are behind some of this variation. A second BCG vaccination given 4 weeks after the first was equivalent in protection to that of a single BCG vaccination in guinea pigs [10] , but when the interval between the vaccinations was much longer (11 months), revaccination was significantly better than single BCG vaccination. In humans, BCG revaccination does not confer additional protection against the development of tuberculosis [11] [12] [13] , and this strategy is not endorsed by the WHO [14] . However, Hatherill et al reported that BCG revaccination of adults infected with M. tuberculosis is safe, that it has a reactogenicity profile similar to that of a single BCG vaccination at birth, and that clinical trials of live recombinant BCG or attenuated mycobacterial vaccines may be considered for targeted populations, including adults with latent M. tuberculosis infection [15] . This opens the possibility of using revaccination with novel live attenuated vaccines, rather than subunit vaccines, to stimulate immunity in adults in whom the protection afforded by neonatal BCG vaccination has waned. Over the past decade, several recombinant live attenuated mycobacterial vaccines [6, 7, [16] [17] [18] [19] [20] have been developed, and some have been evaluated in first-in-human phase 1 clinical trials because they are safer than BCG and or afforded greater protection in preclinical animal models. Today, only 2 live attenuated vaccines are moving through the clinical development pipeline toward efficacy testing in high-burden countries. One is the recombinant BCG∆ureC::hly vaccine (VPM1002), which has successfully reached phase 2a safety and immunogenicity evaluation in healthy newborns (clinical trials registration NCT02391415). The other is MTBVAC, composed of a live attenuated M. tuberculosis strain with 2 deleted genes, phoP and fadD26, which are essential for M. tuberculosis virulence, and constructed in the genetic background of the clinical isolate Mt103 [16] . In rigorous preclinical (and Good Manufacturing Practices) characterization studies, MTBVAC has shown promising safety and efficacy in different, relevant animal models of tuberculosis [16] . As a result, MTBVAC successfully entered first-in-human phase 1 clinical evaluation in healthy adults in Lausanne, Switzerland, in 2013 [21] . This first-ever phase 1 trial with a vaccine of this kind is considered a milestone in tuberculosis vaccinology. Currently, MTBVAC is being tested for safety and immunogenicity in healthy newborns in South Africa (clinical trials registration NCT02729571), as its main target product profile is as a preventive newborn tuberculosis vaccine that could eventually replace BCG [22] . MTBVAC is also being developed as a preventive vaccine for use in adolescents and adults (who received BCG at birth) living in high-burden countries. It is estimated that vaccines targeted at adolescents and adults could have a greater impact on the tuberculosis burden over a short time horizon (2024-2050) and could also be cost-effective [23, 24] .
The present work sought to investigate, preclinically, the effects of revaccination strategies with 2 live mycobacterial vaccines, BCG and MTBVAC, delivered individually and in combination. The principal aim was to determine whether the efficacy of a single BCG vaccination could be affected upon revaccination. We used a guinea pig aerosol-based challenge model of M. tuberculosis infection to compare revaccination regimens with respect to their ability to limit bacterial replication in lungs and spleens. Since the interval between 2 consecutive BCG vaccinations influenced efficacy in previous studies, the effect of short and long prime-boost intervals was evaluated. The effect of the length of time before challenge on the efficacy of BCG or MTBVAC given as single vaccines was also determined.
METHODS

Vaccinations
Studies were conducted according to the United Kingdom Home Office Legislation for animal experimentation and approved by a local ethical committee at Public Health England (Porton Down, United Kingdom). Dunkin Hartley guinea pigs (weight, 250-350 g) free from pathogen-specific infection were randomly assigned to vaccine groups and identified using subcutaneously implanted microchips (Plexx, the Netherlands) to enable blinding of the analyses wherever possible. Group sizes were determined by statistical power calculations (Minitab, version 16) performed using previous data (SD, approximately 0.5) to reliably detect a difference of 1.0 log 10 in the median number of colony-forming units (CFU) per milliliter.
MTBVAC was produced and characterized by Biofabri (Porriño, Spain) in compliance with good manufacturing practices as a freeze-dried preparation, in accordance with protocols in the European Pharmacopoeia monograph and the WHO Recommendations to Assure the Quality, Safety, and Efficacy of BCG Vaccines. The BCG was a commercial formulation of the Danish strain from Statens Serum Institute (Copenhagen, Denmark).
Waning BCG Efficacy Study
Two groups of animals were immunized subcutaneously on the nape with 5 × 10 4 CFU of BCG (SSI) in a volume of 250 µL at 11 months (n = 6) or 3 months (n = 8) before infection. An unvaccinated group (n = 8) was used as a negative control. All animals were rested before challenge by the aerosol route.
Heterologous Revaccination Study
The schedule for the different immunization groups is shown in Figure 1 . At week 0 for groups 5-8 and week 14 for groups 1-4, animals were immunized subcutaneously on the nape with 5 × 10 4 CFU of BCG (SSI) in a volume of 250 µL or with 5 × 10 5 CFU MTBVAC in a volume of 100 µL. Animals in groups 1, 2, 5, and 6 were revaccinated 6 weeks (groups 1 and 2) or 20 weeks (groups 5 and 6) after the prime vaccination. Animals were revaccinated subcutaneously with either BCG (SSI; 5 × 10 4 CFU in 250 µL) or MTBVAC (5 × 10 5 CFU in 100 µL), as described for prime vaccination. Following immunization, all animals were rested until challenge at week 30.
Challenge
Challenge for each study was by the aerosol route with M. tuberculosis strain H37Rv grown in batch culture under defined conditions [25] . The animals were challenged using a contained Henderson apparatus in conjunction with an AeroMP control unit as previously described [10, 26, 27] . The challenge suspension was adjusted to deliver an estimated retained, inhaled, low dose of approximately 10-20 CFU to the lungs of each animal [26] . The suspension of M. tuberculosis in the nebulizer was plated onto Middlebrook 7H11 OADC selective agar to measure the concentration and confirm retrospectively that the expected dose had been delivered.
Assessment of Protection
Protection was determined by measuring the bacterial burden 4 weeks (in the heterologous revaccination study) or 10 weeks (in the waning BCG study) after challenge, when guinea pigs were killed by an overdose with sodium pentobarbital given by the intraperitoneal route. At necropsy, lungs and spleens were removed as described previously [28] .
For bacterial load analysis, each tissue was homogenized in 5 mL (in the waning BCG study) or 2 mL (in the heterologous revaccination study) of sterile phosphate-buffered saline (PBS). Each tissue homogenate was serially diluted in sterile PBS, and 100 µL of each dilution was plated in duplicate onto Middlebrook 7H11 OADC selective agar. Plates were incubated at 37°C for up to 4 weeks. Following incubation, colonies were enumerated (as CFU), and the concentration of bacilli per milliliter of each sample was calculated. Bacterial load data were expressed as log 10 CFU per milliliter.
Histological analysis was performed only on specimens from the heterologous revaccination study. Tissue representative of each lung, sampled consistently between animals, was processed routinely (by formaldehyde fixation) and embedded in paraffin wax. Sections (thickness, approximately 5 μm) were stained with hematoxylin and eosin. The nature and severity of the lesions were assessed by a blinded investigator, using a subjective scoring system. Each lung lobe was assigned a score as previously described [29] . Scores from each lobe were combined. A mean score from lung lobes was calculated for each group. Group mean histopathology scores were compared between groups and with bacterial loads.
Statistical Analysis
Efficacy was determined by pair-wise comparisons between each vaccine group and the control group and were considered statistically significant if the P value was < .05. The bacterial load in each vaccine group for all experiments was compared using Mann-Whitney test. No adjustment was made for multiple comparisons between different vaccine groups versus the control. Histology scores in each vaccine group were compared using a 2-group t test (Minitab, version 16).
RESULTS
Waning BCG Efficacy Study
A single BCG vaccination given 3 months before infection provided significant protection from disease (ie, it yielded a reduced bacterial load) in lungs (P = .0014) and spleens (P = .01), compared with protection observed in the unvaccinated control group (Figure 2 ). However, this protective effect was lost in lungs (P = .12) and spleens (P = .06) when the interval between BCG vaccination and infection was increased to 11 months. No significant differences were observed in the lungs (Figure 2A ) or spleens ( Figure 2B ) when directly comparing the 2 BCG groups (P = .12 and P = .14, respectively).
Heterologous Revaccination Study
In both lungs and spleens, all vaccine groups had significantly improved protection, compared with the unvaccinated control group (Figure 3) .
In the lungs, with a short revaccination interval, BCG prime-MTBVAC revaccination (P = .02) and MTBVAC prime-BCG revaccination (P = .04) groups had significantly lower CFU, compared with the group that received BCG alone. The BCG prime-MTBVAC revaccination group had significantly lower CFU (P = .02) following a long revaccination interval, compared with the BCG-alone group, whereas the MTBVAC-BCG group had a bacterial load equivalent to that of the BCG-alone group (P = .27; Figure 3) .
The MTBVAC-alone group had significantly lower CFU (P = .03), compared with the BCG-alone group, when given 30 weeks prior to challenge, whereas the 2 vaccines yielded equivalent efficacy (P = .23) when vaccination was 16 weeks prior to challenge. No significant difference was observed between the BCG-only groups (P = .09; Figure 3 ).
In the spleens, M. tuberculosis was not observed in animals that received the BCG prime-MTBVAC revaccination (short interval) regimen or BCG alone (<5 CFU/mL). CFU were detected in 1 of 8 animals in each of the other vaccine groups except for the BCG-alone group with a long interval, for which CFU were observed in 2 of 8 guinea pigs.
Histopathological Findings
All vaccine groups had a statistically significantly lower group mean lung and spleen histopathology score, compared with the unvaccinated control group, except for the MTBVAC-BCG regimen with a long interval (P = .07). In the lung, the severity of microscopic lesions was similar in showed similar pathologies in all of the vaccinated groups and were notably less severe than findings for unvaccinated controls. Lesions were not observed in the spleens of animals from the vaccine groups, except for those that received the BCG-MTBVAC (long interval) and MTBVAC-BCG (long interval) regimens. However, lesions were observed in the spleens of 1 animal from each of those groups.
DISCUSSION
Novel live attenuated vaccines and regimens are being developed to replace the current BCG regimen with a safer and efficacious vaccination regimen. MTBVAC is based on the genetic deletions of 2 major virulence factors, the transcription factor regulator PhoP and the virulence associated cell-wall lipid PDIM, from a clinical isolate of the Euro-American M. tuberculosis lineage, which is the most widespread lineage commonly transmitted between humans by the aerosol route [16] . MTBVAC is the only live attenuated M. tuberculosis vaccine candidate in clinical development, presenting a full spectrum of specific mycobacterial antigens to the host immune system, which is highly desirable for a tuberculosis vaccine, since protective antigens are yet to be definitively identified [30] . In the first-in-human phase 1a trial in healthy, BCG-naive, human immunodeficiency virus-uninfected adults in Switzerland, MTBVAC was safe, with similar reactogenicity to that of the licensed BCG vaccine (BCG Vaccine SSI) and demonstrated robust immunogenicity in a dose-dependent manner [21] .
Building on convincing results from phase 1a studies, clinical development of MTBVAC is advancing into 2 specific target populations, healthy neonates and M. tuberculosis-uninfected and -infected adults. In September 2015, MTBVAC entered a phase 1b safety and immunogenicity study in newborns, with a safety arm composed of M. tuberculosis-uninfected healthy adults who received BCG at birth (clinical trials registration NCT02729571). Most adults in tuberculosis-endemic countries have received BCG in infancy and have been exposed to M. tuberculosis. Demonstration of safety, immunogenicity, and optimal dose selection in an adult study population in tuberculosis-endemic settings is key to the advancement of MTBVAC into adult efficacy trials. In the present study, we used a revaccination approach combining Mycobacterium bovis BCG with the live attenuated M. tuberculosis vaccine MTBVAC to evaluate whether the efficacy (and safety) of BCG would be affected upon revaccination with MTBVAC, expecting no interference between both vaccines. Previous efficacy data yielded by the standard short-term guinea-pig protection experiment, which evaluated 3 independent dose levels of MTBVAC (5 × 10 3 CFU, 5 × 10 4 CFU, and 5 × 10 5 CFU) by the subcutaneous route, showed similar protection that was dose independent 4 weeks after aerosol challenge (16 weeks after vaccination) [16] . Surprisingly, in the present study, the efficacy of BCG was improved following MTBVAC revaccination, and the improved protection afforded by prime MTBVAC was unaffected following BCG revaccination. Although these findings should be confirmed in a repeated experiment, they provide strong support for using MTBVAC in a safe and effective revaccination strategy among adolescents and adults who live in countries where tuberculosis is endemic and has a high burden and who received BCG at birth and are presensitized to M. tuberculosis.
The interval between BCG vaccination and challenge was investigated as an indication of the duration of protective immunity induced by vaccines. This is usually determined by measuring markers of immunological memory [31, 32] but is rarely tested in terms of a delayed interval between vaccination and challenge [33, 34] . In the heterologous revaccination study reported here (Figure 3) , a thirty-week interval between BCG and challenge resulted in reduced efficacy, which was significantly different from that associated with a shorter interval of 16 weeks. In a separate study (Figure 2) , we demonstrated that the efficacy of BCG was lost if the vaccination-to-challenge interval was 11 months. These data support reported studies also demonstrating this effect [35] [36] [37] , and this evidence for waning efficacy of BCG is important to inform future studies because preclinical testing of subunit strategies to boost the efficacy of BCG is often confounded by the potent efficacy of BCG alone. If the boost is given distally from the BCG prime vaccination, there is a greater chance that an improved effect can be observed. Studies involving such long prime-boost intervals can be costly and time consuming, and it would be preferable to be able to demonstrate immunologically that an effective boost response had been induced, to accelerate vaccine development.
In contrast to published data and those reported here on the waning efficacy of BCG, MTBVAC had improved efficacy relative to BCG when the vaccination-to-challenge interval was longer. This suggests that MTBVAC-associated immunity is longer lasting than that of BCG because the protective efficacy of MTBVAC is maintained with a longer interval between vaccination and challenge, whereas the protection afforded by BCG is reduced when compared to the short vaccine-to-challenge interval.
Comparisons of short and long revaccination intervals were made to test the hypothesis that the potency of BCG or other live attenuated priming vaccines is diminished by a heterologous vaccine if given too soon after the prime. The data showed that, if anything, the reverse was true. The combination of BCG and MTBVAC in a revaccination regimen improved protection in the lungs of guinea pigs, compared with the efficacy observed for either vaccine alone. Interestingly, the strongest protection was observed with the short revaccination interval, because only BCG-MTBVAC revaccination performed better than BCG alone with the longer revaccination interval. This implies that the observed effects could be due to a combination of the 2 vaccines giving a stronger immunity to M. tuberculosis infection, rather than due to a boosting of waning BCG immunity. The strong protection of these vaccine regimens was such that very few bacteria could be detected in the spleen, and most were at least below the limit of detection of the CFU assay (Figure 4) . While this demonstrates high levels of potentially sterilizing immunity at the spleen level, it was not possible to determine whether any of the regimens had a significantly stronger protective effect than BCG in the spleen. The histopathological analysis demonstrated that all of the vaccine regimens reduced pathology broadly, in agreement with the primary bacteriological readout. However, the pathology scoring system did not have the sensitivity to differentiate between the BCG-MTBVAC revaccination regimens and BCG. Additionally, the MTBVAC-BCG (long interval) group was significantly protected as compared to the unvaccinated group, based on CFU analysis, but the histopathological analysis indicated that the difference was not statistically significant. This is because the scoring system is semiquantitative, based on the extent and nature of the pathology, rather than on absolute values. Therefore, the histopathological data should be considered only as supportive of the primary readout of vaccine efficacy (yielded by the CFU assay) and not interpreted as a stand-alone marker of efficacy.
A BCG-BCG control was not included in the protection study because published data (preclinical and clinical) suggest that this strategy does not improve protection [9, [11] [12] [13] 28] . However, there are differences in study design between the published studies and those reported here, notably in the intervals between BCG vaccination, revaccination, challenge, and necropsy, which make it difficult to draw precise conclusions. Therefore, BCG-BCG is important as an internal control and must be considered for future studies.
No BCG revaccination strategy is currently supported, as described in the WHO position paper [12] [13] [14] [15] , and our own preclinical studies in guinea pigs support the view that revaccination with BCG does not provide greater efficacy than that of a single dose of BCG in the guinea pig [28] . Basabara et al have reported that multiple vaccinations with BCG can have adverse effects when guinea pigs are subsequently challenged with M. tuberculosis, with exacerbation of pathology and excessive inflammation [9] . No such worsening of pathology was observed in our studies, and the pathological changes were either similar or fewer in animals given BCG and MTBVAC than those in animals in which the single vaccines were given. There are several differences between the study by Basaraba et al and our study, particularly with regard to the number of vaccinations (3 vs 2, respectively) and the intervals between each inoculation (3 vs 6 or 20, respectively), and any of these differences may explain the lack of adverse events seen in our study. Moreover, revaccination with a novel live attenuated vaccine such as MTBVAC may be deemed an improvement to a BCG-BCG regimen because MTBVAC contains all of the genes present in the BCG vaccine strain plus the M. tuberculosis genes deleted in M. bovis and the BCG vaccine strain, including the human T-cell epitopes lost in the BCG vaccine strain [38] . It is our hypothesis that a vaccine such as MTBVAC, based on the human M. tuberculosis pathogen, should be more efficient at inducing specific protective immunity against human tuberculosis caused by M. tuberculosis. Most if not all of the novel live vaccines in clinical trials are safer than BCG and offer a better prospect for use in people with latent M. tuberculosis infection [15] . For example, new vaccines, including MTBVAC, have demonstrated reduced reactivity [16] . In addition, clinical trials of the novel live vaccines that are currently ongoing include cohorts that receive both BCG and the novel vaccine (NCT02729571). Preclinical studies such as the strategy described in this article could provide important safety data in preparation for and in support of MTBVAC clinical trials in populations that have previously received BCG (mainly individuals living in tuberculosis-endemic countries).
Preclinical investigation of revaccination is important to provide data for clinical trials in which novel vaccines may be given in human populations in which BCG has been or will be delivered [39] . Here we report an evaluation of the protective efficacy of MTVBAC and BCG in revaccination regimens. These results suggest that MTBVAC could be used as an effective vaccine administered at birth and as a revaccination strategy to improve upon BCG in adolescents and adults who were vaccinated at birth and live in countries where tuberculosis is endemic and has a high burden.
Notes
